Track the Kailera Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was reported on 22 April 2026 (Acquisition). Among the most active insiders: Bain Capital Life Sciences Investors, LLC. The full history is openly available.
14
Insider Decl.
n/a
Thresholds
€277m
5 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kailera Therapeutics, Inc. Strong Buy (bullish), based on 5 analysts. Average price target: US$42.40.
49Σ signal
Buys €277mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Kailera Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare genetic diseases. It emphasizes innovation in the field of genome editing-based treatments.